



South African National Essential Medicine List Adult Hospital Level Medication Review Process Component: Medicines for palliative care

MEDICINE REVIEW

1. Executive Summary

Date: November 2022 Medicine (INN): Olanzapine injection, orodispersible

Medicine (ATC): N05AH03

Indication (ICD10 code): Nausea and vomiting in palliative care R11 + (Z51.5)

Patient population: Adult palliative care patients with nausea and vomiting not responding to metoclopramide

Prevalence of condition: 62% to 71% (refs)

Level of Care: Hospital level (Adults)

Prescriber Level: Medical officer

Motivator/reviewer name(s): Trudy Leong, Dalene van Jaarsveld, Rene Krause

PTC affiliation: DVJ – Free State PTC; RK – Western Cape PTC

Key findings

- Background: Currently, haloperidol IM/SC/IV is the standard of care in the management of palliative nausea and vomiting where metoclopramide cannot be tolerated or is ineffective. Haloperidol injections have been discontinued from the South African market.
- We reviewed evidence for efficacy and safety of olanzapine in managing nausea and vomiting in adult palliative care patients.
- In a literature search conducted on 4 November 2022, we identified two systematic reviews that reported on 2 small randomised controlled trials (RCTs), which recruited participants with advanced cancer and malignant bowel obstruction, respectively. Both reviews were rated critically low on appraisal with AMSTAR 2.
- Advanced cancer: In a small randomised placebo controlled trial (n=30) Navari et al (2020) found that oral olanzapine 5mg reduced nausea scores by 8 (95% CI 7 to 8); p<0.001 compared to placebo, on an 11-point numerical rating scale (NRS) which rated nausea from 0 (no nausea) to 10 (severe nausea). Similarly, vomiting improved with a median of 2 fewer vomiting episodes per day (95% CI 2 fewer to 1 fewer vomiting episodes), p<0.001 Olanzapine exposure was not associated with excess sedation or other adverse effects (very low quality evidence).
- → Malignant bowel obstruction: A small, underpowered, open-label RCT (n=16), reported in a letter by Kaneishi et al (2020), found similar reduction in nausea secondary to partial bowel obstructions, for a 3-day treatment course of olanzapine 5 mg/day compared to metoclopramide 20-30 mg/day. There was a change in score of −3.17 (NRS) for olanzapine and −2.38 (NRS) for metoclopramide, p=0.39 (*very low quality evidence*). Note that metoclopramide is a prokinetic and should therefore be avoided in patients with colic or abdominal pain.
- In summary, low to very low certainty evidence suggests that oral olanzapine may be considered in management of nausea and vomiting in advanced cancer or malignant bowel obstruction where metoclopramide is ineffective or not tolerated.

PHC/ADULT HOSPITAL LEVEL EXPERT REVIEW COMMITEE RECOMMENDATION:

Type of recommendation	We recommend against the option and for the alternative (strong)	We suggest not to use the option (conditional)	We suggest using either the option or the alternative (conditional)	We suggest using the option (conditional)	We recommend the option (strong)
				X	

Recommendation: Based on this review, the Adult Hospital Level Committee suggests that oral, oro-dispersable & IM olanzapine be used in adult palliative care patients with nausea and vomiting (N&V) not responding to metoclopramide, as a replacement to haloperidol.

Rationale: Haloperidol IM has been discontinued locally and an alternative for the management of N&V in palliative care patients is required. There is very little evidence to suggest that oral olanzapine may improve N&V and fatigue with no excessive sedation or adverse effects compared to placebo among adult patients with advanced cancer. Olanzapine may be as effective as metoclopramide in reducing N&V in malignant bowel syndrome.

Level of Evidence: Very low certainty evidence

Review indicator: New high-quality evidence of a clinically relevant benefit

NEMLC RECOMMENDATION - MEETING OF 23 FEBRUARY 2023:

NEMLC was in agreement with the recommendation by the Adult Hospital Level Committee & recommended oral, oro-dispersable & IM olanzapine be used in adult palliative care patients with nausea and vomiting (N&V) not responding to metoclopramide, as a replacement to haloperidol.

Monitoring and evaluation considerations

Research priorities

2. Name of author(s)/motivator(s)

Dalene van Jaarsveld, Rene Krause, Trudy Leong

3. Author affiliation and conflict of interest details

DvJ (University of the Free State), RK (University of Cape Town), and TL (Cochrane-SA, Medical Research Council-SA; Right-To-Care as Secretariat support to the PHC/Adult Hospital Level Committee) have no conflict of interests to declare related to olanzapine.

TL is partly supported by the Research, Evidence and Development Initiative (READ-It) project. READ-It (project number 300342-104) is funded by UK aid from the UK government; however, the views expressed do not necessarily reflect the UK government's official policies).

4. Introduction/ Background

Nausea and vomiting are regarded as one of the most distressing symptoms experiences by most palliative care patients (Leach, 2019). It is a common during the last days of life in patients with underlying cancer, heart failure, renal failure, AIDS, etc., and if not treated effectively, will cause deterioration in the patient's experience of quality of life and contribute to care giver distress.

Most palliative care symptom management guidelines, including the Adult Hospital Level Standard Treatment Guidelines (STGs) and Essential Medicine List STG (2019 edition), recommends metoclopramide as first line pharmacological therapy for nausea and vomiting in palliation. Currently, the STGs recommend haloperidol oral or administered intramuscularly or subcutaneously as a second-line option for those with retractable nausea and

vomiting with or without metoclopramide. Haloperidol injection has been withdrawn from the South African market and an alternative agent is required specifically in patients where the oral route is unsuitable.

Olanzapine is an atypical antipsychotic, and its antiemetic action is attributed to dopamine and serotonin antagonist properties. The palliative care formulary (7th edition, p 256) (3) recommends olanzapine as a second-line anti-emetic in patient where symptoms persist despite optimal first-line treatment. However, most RCT evidence is for olanzapine for chemotherapy-induced nausea and vomiting (Sutherland, 2018), and evidence for olanzapine as an antiemetic in palliative care settings (non-chemotherapy related nausea and vomiting in patients with advance disease) has been reported to be case series, case studies and observational studies (Saudemont, 2020).

An evidence review was conducted to study the safety and effectiveness of olanzapine in treating nausea and vomiting in adult palliative patients.

5. Purpose/Objective

Question: Is olanzapine safe and effective for the management of nausea and vomiting in adult palliative care patients compared to haloperidol?

-P: Adult palliative care patients with nausea and vomiting not responding to metoclopramide

-I: Olanzapine injection or orodispersible formulation for intractable nausea and vomiting (with or without metoclopramide)

-C: Haloperidol oral, parenteral

-O: Quality of life, numeric nausea and vomiting rating scores, other validated nausea and vomiting severity scales, number of emetic episodes during trial period, nausea and vomiting diaries, number of breakthrough nausea and vomiting, serious adverse events other adverse effects including somnolence or fatigue

Study designs: Systematic reviews of randomized controlled trials (RCTs) and RCTs, and if these are not available observational studies and guidelines

6. Methods:

a. Data sources

Systematic reviews were sought in PUBMED and Epistemonikos.

b. Search strategy

A search strategy was developed for PubMed and adapted to other databases (Appendix 1).

c. Screening, data extraction and evidence synthesis

Records were screened, followed by text screening by one reviewer (TL). A step-wise approach was taken, screening for systematic reviews, and if these were not available followed by RCTs, then observational studies. Any discrepancies were resolved by consensus. Eligible systematic reviews were appraised using the AMSTAR II Checklist (Shea, 2017). Risk of bias of RCTs were assessed using the Cochrane's RoB 2.0 Tool (Higgins, 2022). Data extraction for included reviews was done by one reviewer (TL) and data was extracted in Table 1. For dichotomous outcomes, risk ratios (RR) with 95% confidence intervals (CI) were reported and reported results from the review were described. Where available, the GRADE (level of certainty) of the evidence was reported (Guyatt, 2008).

d. Excluded studies

Rationale for excluding studies is described in Appendix 3.

7. Results:

a. Search results

Olanzapine_Palliative Nausea&Vomiting_Adult Medicine Review_November 2024

PubMed and Epistemonikos was searched on 4 November 2022, and 29 records were identified for screening. Four duplicates were removed, and 8 were irrelevant. 17 full-text studies were assessed for eligibility; 15 studies were excluded. There were two systematic reviews selected for evidence synthesis. Refer to the Prisma Flow Chart in Appendix 2.

b. Description of systematic reviews

Two systematic reviews that informed Multinational Association for Supportive Care in Cancer guidelines were identified for inclusion:

- Davis et al, 2021: Review within the "MASCC antiemetics in advanced cancer updated guideline" (Davis, 2021a)
- 2) Davis et al, 2021: Review within the "Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update" (Davis, 2021b)

<u>Davis, 2021a (advanced cancer)</u>: For the updated guideline for antiemetics in advanced cancer, Davis et al reviewed RCT evidence for the pharmacological management of nausea and vomiting in advanced cancer patients. Studies related to chemotherapy-related nausea and vomiting, non-pharmacological management of nausea and vomiting in advanced cancer and malignant bowel obstruction were excluded. The review was assessed to be of critically low quality using the AMSTAR 2 tool. See Table 1). Primary outcome was not stated in the review. Outcomes assessed were reduction in chronic generalized nausea and vomiting in advanced cancer and nausea and vomiting associated with opioid therapy

For haloperidol compared to olanzapine, the reviewers found limited RCT evidence, with a paucity of headto-head studies. However, a single well conducted, small placebo-controlled RCT (n=30) showed that olanzapine 5 mg was superior to placebo, amongst patients with advanced cancer with nausea and vomiting unrelated to chemotherapy or radiation (Navari, 2020). At day 7, there was an 8-point reduction in nausea scores in the olanzapine-treated group (95% CI 7 to 8) compared to the placebo arm, p<0.001 (using an 11point numerical rating score, NRS 0 no nausea, 10 severe nausea). Vomiting, fatigue, pain, and well-being improved, and there was no excessive sedation or other toxic effects associated with olanzapine that was reported. The study was assessed to be of moderate risk of bias as one study participant in the placebo group withdrew from the study at day 5, due to persistent nausea and vomiting. Authors suggested further research with larger studies. See Table 2)

<u>Davis, 2021b (MBO)</u>: The systematic review within the "Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update", focused on RCTs for the pharmacologic management of nausea and vomiting in malignant bowel obstruction (MBO) only. Studies on non-pharmacological management and surgical management of MBO were excluded.

The review was assessed to be of critically low quality using the AMSTAR 2 tool. One small placebo controlled RCT of olanzapine was included in the review. (Table 1 and 2)

The small RCT (n=16), reported in a letter (Kaneishi, 2020) showed that olanzapine may be as effective as metoclopramide in reducing nausea secondary to partial bowel obstructions (though, metoclopramide is a prokinetic and should be avoided if there is colic or abdominal pain). Patients with incomplete bowel obstruction and an average nausea score >4 (using NRS) were randomized to olanzapine 5 mg daily or metoclopramide 20–30 mg daily for 3 days. The primary outcome was mean nausea score for 3 days. There was no difference in the reduction in nausea, with a change in nausea score of -3.17 (NRS) for olanzapine vs -2.38 (NRS) for metoclopramide, p=0.39; assessed by systematic reviewers as low quality evidence due to lack of blinding and uncertainty about testing equi-effective doses. Because as the study was assessed as high risk of bias as open-label, study protocol was not available and most of the study details were not reported in the publication, the quality of the evidence was downgraded to very low quality. This was a small, underpowered open-label pilot trial and further research is needed.

Olanzapine_Palliative Nausea&Vomiting_Adult Medicine Review_November 2024

Table 1: AMSTAR assessment of systematic reviews

Systematic review	Recommendation(s)	Appraisal AMSTAR 2
Davis et al, 2021a. MASCC antiemetics in advanced cancer updated guideline. Support Care Cancer. 2021 Dec;29(12):8097-8107. <u>doi:</u> <u>10.1007/s00520-021-06437-w</u>	 Metoclopramide recommended as first-line antiemetic; moderate quality evidence, consistent findings Haloperidol recommended as first-line antiemetic; moderate quality evidence, consistent findings Olanzapine recommended as a second-line antiemetic; moderate quality evidence, generally consistent findings 	Critically low- quality review. See Appendix 4
Davis, 2021b. Medical management of malignant bowel obstruction (MBO) in patients with advanced cancer: 2021 MASCC guideline update. Support Care Cancer. 2021 Dec;29(12):8089-8096 doi: 10.1007/s00520-021-06438-9	 Octreotide recommended as a front-line treatment for inoperable MBO; <i>high quality evidence, consistent findings</i> Metoclopramide suggested as an active antiemetic in the management of MBO; <i>low quality evidence, generally</i> <i>consistent findings</i> Olanzapine suggested as an active antiemetic in the management of MBO; <i>low quality evidence, generally</i> <i>consistent findings</i> Haloperidol suggested as an active antiemetic in the management of MBO; <i>low to very low quality evidence,</i> <i>generally consistent findings</i> 	Critically low- quality review. See Appendix 4

Haloperidol, conventionally has been used to treat breakthrough nausea and vomiting from MBO in randomized trials but has not be compared with other antiemetics (Davis, 2021b).

Table 2: Characteristics of included studies

Author, date	Type of study	Population (n)	Comparators	Primary	Effect sizes	Comments
Davis et al, 2021a.	Systematic review	/ of 1 SR and 3 RCTs, asso	essed as critically lo	w quality.	1	1
cancer updated guideline. Support	Only I RCT was i	related to olanzapine (Nav	ari, 2020) – which i	s described below		
Care Cancer. 2021						
<u>10.1007/s00520-021-06437-w</u>						
Navari et al, 2020. Olanzapine for the treatment of	Double-blind, placebo-	n=30 ($n_1=15$; $n_2=15$)	Intervention: Olanzapine 5	Primary outcome: Reduction in	Olanzapine vs placebo:	Small pilot RCT, consistent with the results of other pilot studies
advanced cancer-related chronic	controlled,	Adults: 16 women, 14	mg/d, orally,	nausea and	-	(Passik, 2002; Harder, 2019;
nausea and/or vomiting: a randomized pilot trial IAMA	multi-center RCT	men Mean age: 63 (39-79) years	days 1-7 ($n_1=15$)	vomiting (using NRS)	<u>Primary outcome:</u> Change in nausea	Macintosh, 2013)
Oncol	nor	Baseline median	(11-10)	1(10)	scores (NRS): -8 (95%	One study participant in the
6(6):895–899 doi:10.1001/jamaoncol.2020.1052	Inclusion criteria -	nausea scores: 9 out of 10 (range 8-10)	vs.	<u>Other outcomes:</u> Nausea_appetite	CI –8 to –7), p<0.001	placebo group withdrew from the study at day 5 due to
<u>doi.10.1001/juillioileoi.2020.1032</u>	outpatients with	10 (lunge, 0 10).	Placebo (n ₂ =15)	fatigue, sedation,	Other outcomes	persistent nausea and vomiting
	with persistent			numeric rating	<u>(difference between</u> study groups):	Overall risk of bias assessment:
	nausea/vomiting			scores; number of	Vomiting episodes/day:	Some concerns
	of chemo- or			emesis episodes	Median -2 (95% CI -2 to -1), p<0.001	Randomisation: Low risk
	radiotherapy in					Deviations from intervention: Low risk
	previous 14 days.				Alternative antiemetic doses/day: difference	Missing outcome data: Some
	- Chronic				not reported	concerns
	nausea present for at least 1				Appetite scores (NRS):	Measurement of outcome:
	week (worst				Median (range) 5 (95%	Low risk
	daily nausea score> 3 on a				CI 5 to 6), p<0.001	• Selection of the reported
	NRS 0-10				Fatigue scores (NRS):	
	scale).				-3 (95% CI-4 to -1), p=0.004	
	Funding:					
					Sedation scores (NRS): -1 (95% CI-2 to 0).	
					p=0.08	
					Pain sores (NRS): -1 (- 2 to 0), p=0.01	
					<i>Well-being scores</i> (<i>NRS</i>): 5 (4 to 5), p<0.01	

Davis, 2021b. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. Support Care Cancer. 2021 Dec;29(12):8089- 8096	Systematic review Only 1 RCT was	v of 1 SR and 3 RCTs, ass related to olanzapine (Kar	essed as critically lo neishi, 2020) – which	w quality. h is described below		
doi: 10.1007/s00520-021-06438-9 Kaneishi, 2020. Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction. Journal of Palliative Medicine. 2020 Jul 1;23(7):880-881. doi.org/10.1089/jpm.2020.0101	Open-label pilot RCT Inclusion criteria: - advanced cancer - average nausea score of >4/10 due to incomplete malignant bowel obstruction (iMBO) Funding: Grant for Research Advancement on Palliative Medicine from the Japanese Society for Palliative Medicine	n=16 Number of participants per comparator group not reported	Intervention: Olanzapine 5 mg/d x 3days vs. Metoclopramide 20–30 mg/d x 3 days	Outcomes: -Change in mean nausea scores (NRS) for 3 days - rate of 30% reduction in NRS score - number of vomiting episodes - satisfaction rating of patients - preference to continue with the treatment - frequency of severe toxicities - adverse events	Olanzapine vs placebo: Change in mean nausea scores over 3days: -3.17 vs -2.38; p=0.39 Rate of 30% reduction in NRS score: 87.5% vs 50%; p = 0.11 Mean difference in vomiting episodes/ day: 2.25 vs 0.85; p=0.83 Patient satisfaction rate: 87.5% vs 75% Preference to continue treatment: 100% vs 50% Frequency of severe toxicities: Most symptoms were of low grade, and no patient chose to stop anti- emetic therapy Adverse events: Both olanzapine & metoclopramide caused drowsiness and dizziness	Lack of blinding and uncertainty about testing equi-effective doses; <i>low certainty evidence</i> . Study results reported in a letter to editor of a journal. Baseline demographics of comparator groups were not reported. Small pilot study, suggest the potential efficacy of olanzapine and metoclopramide against nausea and vomiting in patients with advanced cancer who have iMBO. Overall risk of bias assessment: High risk • <i>Randomisation:</i> Some concerns • <i>Deviations from intervention:</i> High risk • <i>Missing outcome data:</i> High risk • <i>Measurement of outcome:</i> High risk • <i>Selection of the reported</i> <i>results:</i> Some concerns

Conclusion

A review of available RCT evidence of low quality, suggests that oral olanzapine 5mg/daily may reduce nausea scores and vomiting episodes compared to placebo amongst adult patients with advanced cancer and is safe. Amongst patients with malignant bowel obstruction, very low quality evidence there was no difference in the reduction of nausea with olanzapine compared to metoclopramide. Currently, haloperidol injections (discontinued from the South African market), administered IM/SC/IV is the standard of care in the management of palliative nausea and vomiting where metoclopramide cannot be tolerated or is ineffective. Thus, based on low to very low certainty evidence (pilot studies conducted in high income countries), olanzapine oral may be considered as an alternative to metoclopramide in advanced cancer or malignant bowel obstruction. However, research is required to sufficiently address the question of olanzapine for palliation, noting that there is a need for evidence from low-income settings.

Evidence to decision framewo

	JUDGEMENT	EVIDENCE & ADDITIONAL CONSIDERATIONS
ш	What is the certainty/quality of evidence?	a. <u>Nausea/vomiting in advanced cancer</u>
Ō	a. Nausea/vomiting in advanced cancer	Olanzapine (oral) vs placebo: Very low certainty evidence
NCE	High Moderate Low Very low	
DEN		
	h Nausea/vomiting in MBO	h Nausea/vomiting in MBO
E E	Llich Moderate Low Verylew	Olanzapine vs metoclopramide: Very low certainty evidence
C O	High Moderate Low Very low	
Ę	High quality confident in the evidence	
JAL	Moderate quality: mostly confident, but further research may change the effect	
QL	Low quality: some confidence, further research likely to change the effect	
	What is the size of the effect for heneficial	a Nausaa (vomiting in advanced cancer
F	what is the size of the effect for beneficial	0. <u>Nadsed/Volniting in davanced cancer</u> Olanzapine vs placebo:
EFI	outcomes:	Nausea scores reduced (an 11-point numerical rating score, NRS: 0 no nausea.
EN	u. <u>Nausea/ voiniting in advanced curcer</u>	10 severe nausea) by 8 (95% CI 7 to 8); p<0.001 vs placebo
ш Ц	Large Moderate Small None	 Vomiting episodes improved with a median of −2 (95% CI −2 to −1), p<0.001
Ō	h Nausaa (vomiting in MPO	h Nausaa (vamiting in MPO
NCE	b. <u>Nausea, voniting in WBO</u>	D. <u>Nuuseu/voiniting in MBO</u> Olanzanine (oral) vs metoclonramide:
DE	Large Moderate Small None	• No difference in the reduction in payson with a change in score of -2.17 (NPS)
IN:		for olanzapine vs -2.38 (NRS) for metoclopramide, p=0.39
		 Vomiting episodes – not reported
	What is the certainty/quality of evidence?	a. <u>Nausea/vomiting in advanced cancer</u>
Σ	a. <u>Nausea/vomiting in advanced cancer</u>	Olanzapine (oral) vs placebo: very Low certainty evidence
ΗAF	High Moderate Low Very low	
ΥC		
	b. <u>Nausea/vomiting in MBO</u>	b. <u>Nausea/vomiting in MBO</u>
D BO	High Moderate Low Very low	olanzapine vs metoclopramide: Very low certainty evidence
E		
	What is the size of the effect for harmful outcomes?	a. <u>Nausea/vomiting in advanced cancer</u>
Ъ	a. <u>Nausea/vomiting in davanced cancer</u>	Olanzapine (Oral) vs placebo: No sedation or adverse effects reported.
AS CE (Large Moderate Small None	
ENC VRN		
IOI ₩	b. <u>Nausea/vomiting in MBO</u>	b. <u>Nausea/vomiting in MBO</u>
EV	Large Moderate Small None	Olanzapine vs metoclopramide: Not reported
	Do the desirable effects outweigh the undesirable harms?	a. Nausea/vomitina in advanced cancer
ø	a. Nausea/vomiting in advanced cancer	Olanzapine (oral) vs placebo: Favours intervention
ITS MS	Favours Favours control Intervention	
JEF AR	intervention = Control or	
3EN H	Uncertain	
	X	

	JUDGEMENT		EVIDENCE & A	DDITIONAL CO	ONSIDERA	TIONS	
	b. <u>Nausea/vomiting in MBO</u>		b. <u>Nausea/vor</u>	niting in MBO			
	Favours Favours control	Intervention	Olanzapine vs m	etoclopramide	: Uncertain	1	
	intervention	= Control or					
		Uncertain X					
THERAPEUTIC	n/a						
≥	Is implementation of this recommenda	tion feasible?	Olanzapine is cur	rently SAHPRA-	-registered ((including gei	neric products).
FEASABILI'	Yes No	Uncertain	Olanzapine has al for the manageme patients (due to th South African ma	so been considere ent of aggressive le current discom rket).	ed as an alte disruptive tinuation of	ernative to hald disorders and haloperidol i	operidol injection delirium in adult njection from the
	How large are the resource requirement	nts?	Price of medicir	es/ treatment o	course		
	More intensive Less intensive	Uncertain	Direct price comp cannot swallow:	arison using max	ximum dose	es for 3 days A	AND patient
RCE USE			A: Standard of care Haloperidol	Single dose		3-day course)
			IM/SC/IV Haloperidol IM/SC/IV Previous S21 price	R 45,68 ' 5mg 8hrly x 3 days	5	R 411,12	
no			B: Olanzapine				
IES			alternative	Single o	dose	3-da	
æ			Olassasias	100% SEP	60% SEP	100% SEP	60% SEP
			orodispersible	R 8,91	R 5,35	R26,74	R16,04
			Olanzapine alternativ	R 72,84 re treatment: Olazap	R 43,71 pine ODT or li	R218,53 M 5 mg daily x 3	R131,12 3 days
	Is there important uncertainty or varia	bility about how					
CES	much people value the options?						
EFEREN	Minor Major	Uncertain X					
PR	Is the option acceptable to key stakeho	lders?					
VALUES, ACCI	Yes No	Uncertain X					
~	Would there be an impact on health in	equity?					
EQUITY	Yes No	Uncertain					

Version	Date	Reviewer(s)	Recommendation and Rationale
Initial	November 2022	TL, DVJ, RK	NEMLC recommended oral, oro-dispersable & IM olanzapine be used in adult
			palliative care patients with nausea and vomiting (N&V) not responding to
			metoclopramide, as a replacement to haloperidol. Haloperidol IM has been

	discontinued locally and an alternative for the management of N&V in palliative care
	patients is required. Olanzapine may be as effective as metoclopramide in reducing
	N&V in malignant bowel syndrome.

References:

- Charlesworth S. Palliative Care Formulary (7th Edition). London, England: Pharmaceutical Press, 2020.
- Davis M, Hui D, Davies A, Ripamonti C, Capela A, DeFeo G, Del Fabbro E, Bruera E. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. Support Care Cancer. 2021 Dec;29(12):8089-8096. doi: 10.1007/s00520-021-06438-9. [Davis, 2021a]
- Davis M, Hui D, Davies A, Ripamonti C, Capela A, DeFeo G, Del Fabbro E, Bruera E. MASCC antiemetics in advanced cancer updated guideline. Support Care Cancer. 2021 Dec;29(12):8097-8107. doi: 10.1007/s00520-021-06437-w. [Davis, 2021b]
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr 26;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD.
- Harder S, Groenvold M, Isaksen J, Sigaard J, Frandsen KB, Neergaard MA, Mondrup L, Herrstedt J. Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study. Support Care Cancer. 2019 Aug;27(8):2849-2856. doi: 10.1007/s00520-018-4593-3.
- Higgins J et al. Cochrane Handbook, Chapter 8: Assessing risk of bias in a randomized trial, Version 6.3, 2022. https://training.cochrane.org/handbook/current/chapter-08
- Kaneishi K, Imai K, Nishimura K, Sakurai N, Kohara H, Ishiki H et al. Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction. Journal of Palliative Medicine. 2020 Jul 1;23(7):880-881. https://doi.org/10.1089/jpm.2020.0101
- Leach C. Nausea and vomiting in palliative care. Clin Med (Lond). 2019 Jul;19(4):299-301. doi: 10.7861/clinmedicine.19-4-299.
- MacKintosh D. Olanzapine in the Management of Difficult to Control Nausea and Vomiting in a Palliative Care Population: A Case Series. J Palliat Med. 2016 Jan;19(1):87-90. doi: 10.1089/jpm.2015.0224.
- Madariaga A, Lau J, Ghoshal A, Dzierżanowski T, Larkin P, Sobocki J, et al. MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer. Support Care Cancer. 2022 Jun;30(6):4711-4728. doi: 10.1007/s00520-022-06889-8.
- National Department of Health: Essential Drugs Programme. Adult Hospital level STGs and EML, 2019 edition. <u>https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list</u>
- Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, Loprinzi CL. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial. JAMA Oncol. 2020 Jun 1;6(6):895-899. doi: 10.1001/jamaoncol.2020.1052.
- Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, Cooper M, Dugan W. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage. 2002 Jun;23(6):526-32. doi: 10.1016/s0885-3924(02)00391-3.
- Saudemont G, Prod'Homme C, Da Silva A, Villet S, Reich M, Penel N, Gamblin V. The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature. BMC Palliat Care. 2020 Apr 22;19(1):56. doi: 10.1186/s12904-020-00559-4.
- Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017 Sep 21;358:j4008. doi: 10.1136/bmj.j4008.
- Sutherland A, Naessens K, Plugge E, Ware L, Head K, Burton MJ, Wee B. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555. doi: 10.1002/14651858.CD012555.pub2.

Appendix 1: Search strategy

A: PUBMED

Date: 4 November 2022 Search strategy: (((olanzapine) AND (nausea)) AND (palliative care)) AND (vomiting) Filters applied: Systematic reviews Records retrieved: 4 Excluded: 2 Selected: 2 **B: Epistemonikis** Date: 4 November 2022 Search strategy: (title:(olanzapine) OR abstract:(olanzapine)) AND (title:(nausea) OR abstract:(nausea)) AND (title:(vomiting) OR abstract:(vomiting))) OR abstract:((title:(olanzapine) OR abstract:(olanzapine)) AND (title:(nausea) OR abstract:(olanzapine)) AND (title:(nausea) OR abstract:(vomiting))) Filters applied: Systematic reviews, published last 5 years Records retrieved: 25 Excluded: 21 (6 records were duplicates)

Appendix 2: PRISMA flowchart



Modified From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: <u>http://www.prisma-statement.org/</u> **Annendix 3: List of excluded studies**

Autor, year Study (systematic review and meta-analysis, Pharm Pract (Granada). More recent review retrieved Walsh, 2017 2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and wonithing in advanced cancer. Support Care Cancer. 2017 Jan.25(1):333:340 More recent guidelines and supporting review retrieved Saudemont, 2020 The use of olanzapine as an antiemettic in palliative medicine: a systematic review of the ilterature. BMC Pallat Care. 2020 Apr 22:19(1):56. Wrong study designs (considered only if Sts of RCIs or RCIs are not available). Chow, 2021 Olanzapine for the prophylaxis and rescue of chemotherapy- induced nausea and vomiting: a systematic review, meta- analysis, cumulative meta-analysis and regitity assessment of the literature. Support Care Cancer. 2021 Jul;29(7):3439-3459. More recent review retrieved Yoodee, 2017 Efficacy and safety of olanzapine for the prophylaxis and rescue of chemotherapy- induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Apr;112:113-125. More recent review retrieved Wang, 2021 The Balance Between the Effectiveness and Safety for Chemotherapy-induced Nausea and Vomiting of Different Doses of Olanzapine [0 mg Versus 5 mg]: A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30:11:705866. https://pubmed.ncbi.mlm.nih.gov/J4660273/ Jul; 2021 More recent guidelines and supporting review retrieved Intervention of Nausea and Vomiting following High Emetic Risk Chemotherapy. Houged Masce. 2021 Sep 30:11:705866. https://pubmed.ncbi.mlm.nih.gov/J4660273 More recent review and suppor	Appendix 5. List		
Chenkeba, 2017 Olaraphine for chemotherapy-induced nausea and yomiting: systematic review of meta-analysis. Pharm Pract (Granada). 2017 Jan-Mar;15(1):877 More recent review retrieved Walsh, 2017 2016 Updated MASCC/ESMO consensus recommendations: Support Care Cancer. 2017 Jan;25(1):333-340 More recent review retrieved Saudemont, 2020 The use of olanzapine as an autienetic in palliative medicine: a systematic review of the literature. BMC Pallat Care. 2020 Apr 22:19(1):56. Wrong study designs (considered only if Sks of RCI's are not available). Chow, 2021 Olanzapine for the prophylaxis and rescue of chemotherapy- induced nauses and vomiting: a systematic review, meta- analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Jul;27(3):439-3459. More recent review retrieved Yoodee, 2017 Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Sign): A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30:11:708860 More recent review retrieved Wang, 2021 Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12. Interventions for the prevention of acute phase chemotherapy- induced Nausea and Vomiting Following High Temetic Risk Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e247-e357. More recent review retrieved Qiu, 2021 Cast Effectiveness of Aprepitant in Preventi	Autnor, year	Study (systematic review)	Reason for exclusion
systematic review and meta-analysis, Pharm Pract (Granada), 2017 Jan-Marri 5(1):877 More recent guidelines and supporting review retrieved Walsh, 2017 2016 Updated MASCC/ESM0 consensus recommendations: Management of nauses and womiting in advanced cancer. Support Care Cancer. 2017 Jan;25(1):333-340 Wore recent guidelines and supporting review retrieved Saudemont, 2020 The use of olanzapine as an antemetic in palliative meticine: a systematic review of the literature. BMC Palliat Care. 2020 Apr 22;19(1):56. Wrong study designs (considered only if SRs of RCTs or RCTs are not available). Chow, 2021 Olanzapine for the prophylaxis and rescue of chemotherapy- induced nauses and vomiting: a systematic review, meta- analysis, cumulative meta-analysis and reging the sasesment of the literature. Support Care Cancer. 2021 Jul;29(7):3439-3459. Control arm included other agents besides haloperido. Jand did not stratify effect of olanzapine per comparator Wonge, 2017 Efficacy and safety of olanzapine for the prevention of chemotherapy-induced hauses and vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30(1): T05866. https://pubmed.ncbi.mn.nii.gov/J4660273 More recent review and supporting review retrieved Herrstedt, 2017 Intervention of acute phase chemotherapy- induced nause and Vomiting fin diving High Emetic Risk Chemotherapy. Support Care Cancer. 2012 Jan;25(1):277-288. Intervention of Nause and Vomiting Following High Emetic Risk Chemotherapy-induced Nausea and Vomiting: A systematic Review and Network Meta-Analysis. Oncologist. 2019 Worng indicat	Chelkeba, 2017	Olanzapine for chemotherapy-induced nausea and vomiting:	More recent review retrieved
2017 Jan-Mar;15(1):877 More recent guidelines and supporting Management of nauses and vomiting in advanced cancer. More recent guidelines and supporting review retrieved Saudemont, 2020 The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature. BMC Palliat Care. 2020 Apr 22,19(1):56. Wrong study designs (considered only if SR of RCTs or RCTs are not available). Chow, 2021 Olanzapine for the prophylaxis and rescue of chemotherapy- induced nauses and vomiting: a systematic review, meta analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Lul;29(1):343-343. Control arm included other agents besides haloperidd), and din ot straffly effect of olanzapine per comparator Yoodee, 2017 Efficary and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review wand Meta-Analysis. Front Oncol. 2021 Sep 30:11:705866. https://pumberd.ncbi.nlm.nih.gov/34660273/ More recent review retrieved Wang, 2021 Intervention of nucle phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Systematic Review and Meta-Analysis. Front Oncol. 2021 Janz,5(1):277-288. Wrong intervention Wing 12 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting in Agut and pediatric patients: a systematic review and meta-analysis. OptoClarg. 20:29 More recent guidelines and supporting review retrieved Qiu, 2021 Cost: Effectiveness of Aprepitant in Preventing Chemotherapy- induced Nau		systematic review and meta-analysis. Pharm Pract (Granada).	
Walsh, 2017 2016 Updated MASCC/ESMO consensus recommendations: Management of nause and vomiting in advanced cancer. Support Care Cancer. 2017 Jan;25(1):333-340 More recent guidelines and supporting review retrieved Saudemont, 2020 The use of olanzapine as an anternetic in palliative medicine: a analysis, cumulative meta-analysis and frequent review, meta- analysis, cumulative meta-analysis and reprevention of the literature. Support Care Cancer. 2021 Jul;29(7):3439-3459. Control arm included other agents besides haloperidd, and id not stratify effect of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Apr;112:113-125. Worg comparator Wang, 2021 The Balance Between the Effectiveness and Safety of olanuses of Olanzapine (10 mg Versus 5 mg): A systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12. Wrong comparator Patel, 2022 Interventions for the prevention of nuesee and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12. More recent guidelines and supporting review retrieved Qiu, 2021 Cost-Effectiveness of Aprepriatin Proventing Chemotherapy- Induced nausea and Vomiting: A Systematic Review and Interventing Chemotherapy. Induced nausea and Vomiting: A Systematic Review and Neta-Analysis. Support Care Cancer. 2022 Aug 12. Worg intervention Qiu, 2021 Cost-Effectiveness of Aprepriatin In Preventing Chemotherapy. Induced nausea and Vomiting: A Systematic Review and Neta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357. Worg intervention Qiu, 2020 Olanzapine combined with 5-hydroxytryptami		2017 Jan-Mar;15(1):877	
Management of nauses and vomiting in advanced cancer. review retrieved Support Care Cancer. 2017 Jan;25(1):33:340 Wrong study designs (considered only if systematic review of the literature. BMC Pallial Care. 2020 Apr 22:19(1):56. Wrong study designs (considered only if SRs of RCTs or RCTs or RCTs or and valiable). Chow, 2021 Olanzapine for the prophylaxis and rescue of chemotherapy- induced nauses and vomiting: a systematic review, meta- analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 UJJ2(9):1343-3459. Control arm included other agents besides haloperidd, and did not stratify effect of olanzapine per comparator Yoodee, 2017 Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nauses and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Apr;112:131-125. More recent review retrieved Wang, 2021 The Balance Between the Effectiveness and Safety for Chemotherapy-induced nauses and vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Front Onci. 2021 Sep 30:11:705866. Intervention group not specific to olanzapine Herrstedt, 2017 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nauses and Vomiting: A Systematic Review and Aug 12. More recent guidelines and supporting review retrieved Qiu, 2021 Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nauses and Yomiting: A Systematic Review and Neta-Analysis. Oncologist. 2019 Jun;24(6):4347-e357. Worng inderation	Walsh, 2017	2016 Updated MASCC/ESMO consensus recommendations:	More recent guidelines and supporting
Support Care Cancer. 2017 Jan;24:1]:333-340 Wrong study designs (considered only if systematic review of the literature. BMC Palliat Care. 2020 Apr 22:19(1):56. Wrong study designs (considered only if SRs of RCTs or RCTs are not available). Chow, 2021 Olanzapine for the prophylaxis and rescue of chemotherapy- induced nausea and vomiting: a systematic review, meta- analysis, cumulative meta-analysis and frequity assement of the literature. Support Care Cancer. 2021 Jul;29(7):3439-3459. Control arm included other agents besides haloperidd, and did not stratify effect of olanzapine and meta-analysis. A frit Rev Oncol Hematol. 2017 Apr;112:113-125. More recent review retrieved Wang, 2021 The Balance Between the Effectiveness and Safety of olanusea and vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic review and meta-analysis. Support Care Cancer. 2022 Aug; 12. Wrong comparator Wang, 2021 The Balance Between the Effectiveness and Safety of chemotherapy-induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Stront Onci. 2021 Seg 30:11:705866. Wrong comparator Herrstedt, 2017 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting: A Systematic Review and Meta-analysis. Support Care Cancer. 2017 Jan;25(1):277-288. More recent guidelines and supporting review retrieved Qiu, 2021 Cost: Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357. Zhou, , 2020		Management of nausea and vomiting in advanced cancer.	review retrieved
Saudemont, 2020 The use of olarazapine as an antemetic in palliative medicine: a systematic review of the literature. BMC Palliat Care. 2020 Apr 22;19(1):56. Wrong study designs (considered only if SRs of RCTs or RCTs are not available). Chow, 2021 Olarazapine for the prophylaxis and rescue of chemotherapy- induced nausea and vomiting: a systematic review, meta- analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Jul;29(7):3439-3459. Control arm included other agents besides haloperidol, and did not stratify effect of olanazapine per comparator Yoodee, 2017 Efficacy and safety of olanazapine for the prevention of chemotherapy-induced Nausea and Vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Apr;112:113-125. More recent review retrieved Wang, 2021 The Balance Between the Effectiveness and Safety for Chemotherapy-induced Nausea and Vomiting fol Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30:11:705866. Wrong comparator Patel, 2022 Interventions for the prevention of acute phase chemotherapy- induced nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2022 Aug 12. More recent guidelines and supporting review retrieved Qlu, 2021 Cost-Effectiveness of Anzerpitant in Preventing Chemotherapy- induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514. Wrong intervention Yokoe, 2019 Effectiveness of Anzerpitant in Preventing for methore		Support Care Cancer. 2017 Jan;25(1):333-340	
systematic review of the interature. BMC Painal Care. 2020 Apr 22:19(1):56.Sis of KL is or RL is are not available).Chow, 2021Olarazpine for the prophylaxis and rescue of chemotherapy- induced nausea and vomiting: a systematic review, meta- analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Jul;29(7):3439-3459.Control arm included other agents. besides haloperidol, and did not stratify effect of olanzapine per comparatorYoodee, 2017Efficacy and Safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Apr;112:113-125.More recent review retrievedWang, 2021The Balance Between the Effectiveness and Safety for Chemotherapy-induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30;11:705866. https://pubmed.ncbi.nlm.nih.gov/34660273/More recent review retrievedPatel, 2022Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12.More recent guidelines and supporting review retrievedHerrstedt, 2017Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting: A Systematic Review of Published Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Worog indicationQiu, 2021Cost-Effectiveness of Antiemetic Regimens for Highly Emetogenic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olanzapine combined with 5-hydroxytryptam	Saudemont, 2020	The use of olanzapine as an antiemetic in palliative medicine: a	Wrong study designs (considered only if
22(3)(1):5b. Conv, 2021 Olanzapine for the prophylaxis and rescue of chemotherapy- induced nausea and vomiting: a systematic review, meta- analysis, comulative meta-analysis and fragility assement of the literature. Support Care Cancer. 2021 Jul;29(7):3439-3459. Control arm included other agents besides haloperiol), and did not stratify effect of olanzapine per comparator Yoodee, 2017 Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Apr;112:113-125. More recent review retrieved Wang, 2021 The Balance Between the Effectiveness and Safety for Chemotherapy-induced Nausea and Vomiting: A systematic review and meta-analysis. Sprematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30;11:705866. https://pubmed.ncbi.nlm.ing.og/3460273/ Wrong comparator Patel, 2022 Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12. Intervention group not specific to olanzapine Patel, 2017 Updated MASCC/EMO Consensus Recommendations: Prevention of Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Heat. Analysis. Cronologist. 2019 Jun;24(6):e347-e357. Worog intervention Yokoe, 2019 Effectiveness of Antiemetic Regimens for Highly Emetic Risk Chemotherapy-induced Nausea and vomiting: a Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357. Worog intervention Yokoe, 2019 Effectiveness of Antiemetic Regimens for trighly Emetic Risk Chemotherapy-induced Nausea and vomiti		systematic review of the literature. BMC Palliat Care. 2020 Apr	SRS of RCIS or RCIS are not available).
Chow, 2021 Olanzapine for the prophylaxis and rescue of chemotherapy- induced nausea and vomiting: a systematic review, meta- analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Jul;29(7):3439-3459. Control arism included other agents besides haloperido), and did not stratify effect of olanzapine per comparator the uiterature. Support Care Cancer. 2021 Jul;29(7):3439-3459. Yoodee, 2017 Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Apr;112:113-125. More recent review retrieved Wang, 2021 The Balance Between the Effectiveness and Safety for Chemotherapy-induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Fornt Honcol. 2021 Sp 30;11:705866. Wrong comparator Patel, 2022 Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12. More recent guidelines and supporting review retrieved Qiu, 2021 Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25:9:660514. Wrong intervention Yokoe, 2019 Effectiveness of Antiemetic Regimens for rightly Emetogenic Chemotherapy-induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357. Wrong indication Zhou , 2020 Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dex		22;19(1):56.	
Induced nausea and vomiting: a systematic review, meta- analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Jul/29(7):3439-3459. Besides naloperido), and did not stratify effect of olanzapine per comparator Yoodee, 2017 Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Apr;11:2113-125. More recent review retrieved Wang, 2021 The Balance Between the Effectiveness and Safety for Chemotherapy-induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus S mg): A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30;11:705866. Wrong comparator Patel, 2022 Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12. Interventions for the prevention of acute phase chemotherapy- induced Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288. More recent guidelines and supporting review retrieved Qiu, 2021 Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514. Wrong intervention Yokoe, 2019 Effectiveness of Apriepitant in Preventing Chemotherapy- induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(0):e347-e357. Wrong indication Zhou , 2020 Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethason	Chow, 2021	Olanzapine for the prophylaxis and rescue of chemotherapy-	Control arm included other agents
analysis, Culturative meta-analysis and traguity assessment of the literature. Support Care Cancer. 2021 Jul;29(2):339:3459.effect of oinArapine per comparator the intervention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Apr;112:113-125.More recent review retrievedWang, 2021The Balance Between the Effectiveness and Safety for Chemotherapy-induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30;11:705866. https://pubmed.ncbi.nlm.nih.gov/34660273/Wrong comparatorPatel, 2022Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12.Intervention group not specific to olanzapineUiu, 2021Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Jul; 25(1):277-288.More recent guidelines and supporting review retrievedVokee, 2019Effectiveness of Aniemetic Regimens for Highly Emetgenic Chemotherapy-induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong indicationYokue, 2019Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonis (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced Nausea and Vomiting: A Systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar ef		induced nausea and vomiting: a systematic review, meta-	besides haloperidol, and did not stratify
Yoodee, 2017Efficacy and safety of adnazpine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Apr;112:113-125.More recent review retrievedWang, 2021The Balance Between the Effectiveness and Safety for Chemotherapy-induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30;11:705866. https://pubmed.ncbi.ml.m.in.gov/34660273/Wrong comparatorPatel, 2022Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12.Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288.More recent guidelines and supporting review retrievedQiu, 2021Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong interventionYokoe, 2019Effectiveness of Antimene for Highly the metogenic chemotherapy-induced nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olanzapine combined with 5-hydroxytrytamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate metogenic chemotherapy: a systematic review and meta-analysis. Oraclogist. 2020 Dipu;24(6):e347-e357.Wrong indicationSutherland, 2018Olanzapine co		analysis, cumulative meta-analysis and fragility assessment of	effect of olanzapine per comparator
Yoodee, 2017 Efficacy and safety of Dianzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic Apr;112:113-125. More recent review retrieved Wang, 2021 The Balance Between the Effectiveness and Safety for Chemotherapy-induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30;11:705866. https://pubmed.ncbi.nlm.nih.gov/34660273/ Wrong comparator Patel, 2022 Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12. Interventions for the prevention of Support Care Cancer. 2017 Aug 12. Herrstedt, 2017 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting: Following High Emetic Risk Chemotherapy.org Care Cancer. 2017 Jan;25(1):277-288. More recent guidelines and supporting review retrieved Qiu, 2021 Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review and Netork Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357. Wrong indication Zhou , 2020 Olanzapine combined with 5-hydroxytryptamine type 3 receptor anatgonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and Netork American patients with bipolar disorder have similar efficary, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270. More recent review retrieved	V 1 2017	the literature. Support Care Cancer. 2021 Jul;29(7):3439-3459.	
Chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Apr;112:113-125.Wrong comparatorWang, 2021The Balance Between the Effectiveness and Safety for Chemotherapy-induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30;11:705866. https://pubmed.ncbi.nim.nih.gov/34660273/Wrong comparatorPatel, 2022Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12.Intervention sfor the prevention of acute phase chemotherapy- induced nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan.25(1):277-288.More recent guidelines and supporting review retrievedQiu, 2021Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong indicationYokoe, 2019Effectiveness of Antiemetic Regimens for Highly Emetogenic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olarzapine combined with 5-hydroxytryptamine type 3 receptor antagonis (5-HT3 RA) plus dexametabasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemothreapy as systematic review and meta-analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy. Joleandist, Sorthage and vomiting in adults. Cochrane Database Syst Rev. 	Yoodee, 2017	Efficacy and safety of olanzapine for the prevention of	More recent review retrieved
PerformancePerformationCurr Rev Uncon Hematol. 2017Apri12:113-125.Wang, 2021The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vorniting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30;11:705866. https://pubmed.ncbi.nlm.nih.gov/34660273/Wrong comparatorPatel, 2022Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12.Intervention group not specific to olanzapineHerrstedt, 2017Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288.More recent guidelines and supporting review retrievedQiu, 2021Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong indicationYokoe, 2019Effectiveness of Antiemetic Regimens for Prevention and treatment of chemotherapy-induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(5):e347-e357.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vorniting in adults. Cochrane Database Syst Rev. 2018 Sep 21:9(9):C0012555.More rec		chemotherapy-induced nausea and vomiting: A systematic	
Wang, 2021 The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30:11:705866. https://pubmed.ncbi.nlm.nih.gov/34660273/ Wrong comparator Patel, 2022 Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12. Interventions for the prevention of acute phase chemotherapy- induced Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288. More recent guidelines and supporting review retrieved Qiu, 2021 Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514. Wrong indication Yokoe, 2019 Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357. Wrong indication Zhou , 2020 Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621. Wrong indication Bai, 2020 Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clini		review and meta-analysis. Crit Rev Oncol Hematol. 2017	
Wang, 2021 The Balance between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Yomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30;11:705866. Wrong comparator Patel, 2022 Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12. Intervention group not specific to olanzapine Herrstedt, 2017 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288. More recent guidelines and supporting review retrieved Qiu, 2021 Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Wrong intervention Yokoe, 2019 Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Wrong indication Zhou , 2020 Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate metogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621. Wrong indication Bai, 2020 Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trial		Apr;112:113-125.	
Chemotherapy-induced Nausea and Vomiting or Uniterent Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis. Front Oncol. 2021 Sep 30;11:705866. https://pubmed.ncbi.nlm.nih.gov/34660273/Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12.Interventions for the prevention of acute phase chemotherapy- induced MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288.More recent guidelines and supporting review retrievedQiu, 2021Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25:9:60514.Wrong indicationYokoe, 2019Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):8347-857.Wrong indicationZhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jun; 24(1):e307-e365.Wrong indicationBai, 2020Olanzapine for the prevention and treatment of ca	wang, 2021	The Balance Between the Effectiveness and Safety for	wrong comparator
Dianappine (LD mg versus 5 mg): A systematic Review and Meta-nalysis. Front Occol. 2021 Sep 30;11: 705866. https://pubmed.ncbi.nlm.nih.gov/34660273/ Intervention group not specific to olanappine Patel, 2022 Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12. Intervention group not specific to olanappine Herrstedt, 2017 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288. More recent guidelines and supporting review retrieved Qiu, 2021 Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514. Wrong intervention Yokoe, 2019 Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357. Wrong indication Zhou , 2020 Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT 3RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621. Wrong indication Bai, 2020 Asian and North American patients with biploar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychot		Chemotherapy-induced Nausea and Vomiting of Different Doses	
InterventionInterventionIntervention of acute play, 11,03806.Patel, 2022Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12.Intervention group not specific to olanzapineHerrstedt, 2017Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288.More recent guidelines and supporting review retrievedQiu, 2021Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong interventionYokoe, 2019Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong interventionZhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (S-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and Meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;(51):e000621.Wrong indicationBai, 2020Asian and North American patients with biplard disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting in andults. Cochrane Databa		Mata Analysia Front Oncel 2021 Son 20:11/705866	
Integs.//publick.inclumination.gov/s4002/3/ Patel, 2022Interventions for the prevention of acute phase chemotherapy- induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12.Interventions for olanzapineHerrstedt, 2017Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288.More recent guidelines and supporting review retrievedQiu, 2021Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong interventionYokoe, 2019Effectiveness of Anteimetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemothrelapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.More recent review retrievedSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent 2021 re		https://pubmod.pcbi.plm.pib.gov/24660272/	
Patel, 2022Interventions for the prevention of actue phase chemotherapy- induced nause and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12.Intervention for specific to olanzapineHerrstedt, 2017Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288.More recent guidelines and supporting review retrievedQiu, 2021Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong interventionYokoe, 2019Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy as systematic review and Meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.More recent review retrievedSutherland, 2018Olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):C0012555.More recent 2021 review retrievedYang, 2017 <td>Datal 2022</td> <td>Interventions for the provention of courts phase characteristic</td> <td></td>	Datal 2022	Interventions for the provention of courts phase characteristic	
Induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. Support Care Cancer. 2022 Aug 12.OlanzapineHerrstedt, 2017Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288.More recent guidelines and supporting review retrievedQiu, 2021Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong interventionYokoe, 2019Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (S-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong interventionBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.More recent review retrievedSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent 2021 review retrievedYang, 2017Efficacy to lanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting in adults. Co	Patel, 2022	induced neuron and usersiting in adult and padietric netionary	Intervention group not specific to
Systematic review and infecta-analysis. Support Care Cancer. 2022Herrstedt, 2017Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288.More recent guidelines and supporting review retrievedQiu, 2021Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong interventionYokoe, 2019Effectiveness of Antimetic Regimens for Highly Emetogenic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (S-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and Neta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong interventionBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul;83(7):1369-1379.More recent 2021 review retrieved		induced hausea and vomiting in adult and pediatric patients: a	olanzapine
Herrstedt, 2017Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288.More recent guidelines and supporting review retrievedQiu, 2021Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong interventionYokoe, 2019Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olarapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e006521.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent z021 review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul;83(7):1369-1379.More recent 2021 review retrieved		Systematic review and meta-analysis. Support Care Cancer. 2022	
Thersteed, 2017Opticated WASCC Junc Consusts Recommendations Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288.Induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong interventionYokoe, 2019Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olarazapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e00621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. B J Clin Pharmacol. 2017 Jul;83(7):1369-1379.More recent 2021 review retrieved	Horrstodt 2017	Aug 12.	More recent guidelines and supporting
Chemotherapy. Support Care Cancer. 2017 Jan;25(1):277-288.Tevel Vet	Hensteut, 2017	Brovention of Nausoa and Vemiting Following High Emotic Pick	roviow retrieved
Qiu, 2021Chemotherapy: Jupport care Cancer 2017 Jan, 2517 F200.Wrong interventionQiu, 2021Cost-Effectiveness of Aprepitant in Preventing Chemotherapy- Induced Nausea and Vomiting: A Systematic Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong interventionYokoe, 2019Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and voniting: a meta-analysis. Br J Clin Pharmacol. 2017, Jul;83(7):1369-1379.More recent 2021 review retrieved		Chemotherapy Support Care Cancer, 2017 Jap 25(1):277-288	
Club, 2021Cost-Fried Ventices of Aprephatic in Preventing Clebin (Review of Published Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong interventionYokoe, 2019Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.More recent 2021 review retrieved	Oiu 2021	Cost-Effectiveness of Aprenitant in Preventing Chemotherapy-	Wrong intervention
Articles. Front Public Health. 2021 Aug 25;9:660514.Wrong indicationYokoe, 2019Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.More recent 2021 review retrieved	Q10, 2021	Induced Nausea and Vomiting: A Systematic Review of Published	wrong intervention
Yokoe, 2019Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong interventionBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul;83(7):1369-1379.More recent 2021 review retrieved		Articles Front Public Health 2021 Aug 25:9:660514	
Tokoc, 2013Enclotencies of Anticipite Regiments for Fighty Enclogence Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2019 Jun;24(6):e347-e357.Wrong indicationZhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.More recent 2021 review retrieved	Vokoe 2019	Effectiveness of Antiemetic Regimens for Highly Emetogenic	Wrong indication
Initial and provide the properties of the properti	10000, 2015	Chemotherany-Induced Nausea and Vomiting: A Systematic	
Jun;24(6):e347-e357.Wrong interventionZhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong interventionBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.More recent 2021 review retrieved		Review and Network Meta-Analysis Oncologist 2019	
Zhou , 2020Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong interventionBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.More recent 2021 review retrieved		lun:24(6):e347-e357	
End (2010)Contract with a hydrony type and type a free proceeded in the hydrony type and type a	Zhou 2020	Olanzanine combined with 5-hydroxytryntamine type 3 recentor	Wrong intervention
Integration (g) from the problem of the mother apy-induced nausea and vomiting in high and moderate emetogenic chemother apy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.More recent 2021 review retrieved	21100 , 2020	antagonist (5-HT3 RA) plus dexamethasone for prevention and	
high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.More recent 2021 review retrieved		treatment of chemotherapy-induced nausea and vomiting in	
review and meta-analysis of randomised controlled trials. ESMO Open. 2020 Feb;5(1):e000621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.More recent 2021 review retrieved		high and moderate emetogenic chemotherapy: a systematic	
Open. 2020 Feb;5(1):e000621.Wrong indicationBai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.More recent 2021 review retrieved		review and meta-analysis of randomised controlled trials. ESMO	
Bai, 2020Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.Wrong indicationSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.More recent 2021 review retrieved		Open. 2020 Feb;5(1):e000621.	
Summary 2017Interference similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord. 2020 Jan 15;261:259-270.More recent review retrievedSutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.More recent 2021 review retrieved	Bai, 2020	Asian and North American patients with bipolar disorder have	Wrong indication
Sutherland, 2018Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555.More recent review retrievedYang, 2017Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.More recent 2021 review retrieved	200, 2020	similar efficacy, tolerability, and safety profile during clinical	
15;261:259-270. Sutherland, 2018 Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555. More recent review retrieved Yang, 2017 Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis. Br J Clin More recent 2021 review retrieved Pharmacol. 2017 Jul:83(7):1369-1379. Pharmacol. 2017 Jul:83(7):1369-1379. More recent 2021 review retrieved		trials with atypical antipsychotics? J Affect Disord, 2020 Jan	
Sutherland, 2018 Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555. More recent review retrieved Yang, 2017 Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379. More recent 2021 review retrieved		15:261:259-270.	
nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555. Yang, 2017 Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379. More recent 2021 review retrieved	Sutherland. 2018	Olanzapine for the prevention and treatment of cancer-related	More recent review retrieved
2018 Sep 21;9(9):CD012555. Yang, 2017 Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol, 2017 Jul:83(7):1369-1379.		nausea and vomiting in adults. Cochrane Database Syst Rev.	
Yang, 2017 Efficacy of olanzapine for the prophylaxis of chemotherapy- induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.		2018 Sep 21;9(9):CD012555.	
induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul:83(7):1369-1379.	Yang, 2017	Efficacy of olanzapine for the prophylaxis of chemotherapy-	More recent 2021 review retrieved
Pharmacol. 2017 Jul:83(7):1369-1379.	U, -	induced nausea and vomiting: a meta-analysis. Br J Clin	
		Pharmacol. 2017 Jul;83(7):1369-1379.	

Chiu, 2021	Secondary and cumulative meta-analysis of olanzapine for	Control arm included other agents
	antiemetic prophylaxis for chemotherapy-induced nausea and	besides haloperidol, and did not stratify
	vomiting: do we still need to study its effectiveness? Ann Palliat	effect of olanzapine per comparator
	Med. 2021 Mar;10(3):2540-2547.	
Alhifany, 2020	Efficacy of olanzapine, neurokinin-1 receptor antagonists, and	Wrong comparator
	thalidomide in combination with palonosetron plus	
	dexamethasone in preventing highly emetogenic chemotherapy-	
	induced nausea and vomiting: a Bayesian network meta-	
	analysis. Support Care Cancer. 2020 Mar;28(3):1031-1039.	
Jahn, 2022	The Prevention and Treatment of Nausea and Vomiting During	Narrative review
	Tumor Therapy. Dtsch Arztebl Int. 2022 May 27;119(21):382-	
	392.	
Xiao, 2022	A pooled analysis of adding olanzapine to guideline-	Wrong population group (specific to
	recommended antiemetic therapy for breast cancer patients	breast cancer patients), wrong study
	treated with an anthracycline and cyclophosphamide in	design
	prospective and retrospective studies. Support Care Cancer.	
	2022 Mar;30(3):2445-2453. 34775535.	
Zhang, 2018	Olanzapine-Based Triple Regimens Versus Neurokinin-1	Wrong intervention
	Receptor Antagonist-Based Triple Regimens in Preventing	
	Chemotherapy-Induced Nausea and Vomiting Associated with	
	Highly Emetogenic Chemotherapy: A Network Meta-Analysis.	
	Oncologist. 2018 May;23(5):603-616.	
Bahbah, 2019	Should Olanzapine be Advocated Over Conventional Anti-	Control arm included other agents
	Emetics for the Prevention of Chemotherapy-Induced Nausea	besides haloperidol, and did not stratify
	and Vomiting? An Updated Meta-Analysis of Randomized	effect of olanzapine per comparator
	Control Trials. Current Enzyme Inhibition. 2019;	
Solmi, 2020	Safety of 80 antidepressants, antipsychotics, anti-attention-	Wrong indication
	deficit/hyperactivity medications and mood stabilizers in	
	children and adolescents with psychiatric disorders: a large scale	
	systematic meta-review of 78 adverse effects. World Psychiatry.	
	2020 Jun;19(2):214-232.	

Appendix 4: AMSTAR 2 assessment

		Yes/ Partial Yes/ No	
No	Criteria	Davis, 2021a	Davis, 2021b
1	Research questions and inclusion criteria for the review included the components of PICO	Partial yes	Partial yes
2*	Report of the review contained an explicit statement that the review methods were established prior to the conduct of the review and did the	No, not explicit	No, not explicit
	report justify any significant deviations from the protocol		
3	Review authors explained selection of the study designs for inclusion in the review	No	No
4*	Review authors used a comprehensive literature search strategy	Partial yes	Partial yes
5	Review authors perform study selection in duplicate	Yes	Yes
6	Review authors perform data extraction in duplicate	Yes	Yes
7	Review authors provided a list of excluded studies and justify the exclusions	No	No
8*	Review authors described the included studies in adequate detail	Yes	Yes
9	Review authors used a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review	No	No
10*	Review authors reported on the sources of funding for the studies included in the review?	No	No
11	For meta-analyses, review authors used appropriate methods for statistical combination of results	n/a	n/a
12*	For meta-analyses, review authors assessed the potential impact of RoB in individual RCTs on the results of the meta-analysis or other evidence	n/a	n/a
	synthesis		
13	Review authors accounted for RoB in individual RCTs when interpreting/ discussing the results of the review	No	No
14*	Review authors provided a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review	n/a	n/a
15	For quantitative synthesis, review authors carried out an adequate investigation of publication bias (small study bias) and discussed its likely impact on the results of the review	No	No
16*	Review authors reported any potential sources of conflict of interest, including any funding they received for conducting the review	Yes	Yes

* Critical domains

• High: No or one non-critical weakness: the systematic review provides an accurate and comprehensive summary of the results of the available studies that address the question of interest

• Moderate: More than one non-critical weakness*: the systematic review has more than one weakness but no critical flaws. It may provide an accurate summary of the results of the available studies that were included in the review

• Low: One critical flaw with or without non-critical weaknesses: the review has a critical flaw and may not provide an accurate and comprehensive summary of the available studies that address the question of interest

• Critically low: More than one critical flaw with or without non-critical weaknesses: the review has more than one critical flaw and should not be relied on to provide an accurate and comprehensive summary of the available studies (*Multiple non-critical weaknesses may diminish confidence in the review and it may be appropriate to move the overall appraisal down from moderate to low confidence).

OVERALL ASSESMENT: Critically low

Rationale: More than one critical flaw (# 2,10)

Conclusion: The AMSTAR assessment suggests that both reviews have more than one critical flaw and should not be relied on to provide an accurate and comprehensive summary of the available studies.